Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.81 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Wai Yuen Tong Medicine Holdings's Beneish M-Score or its related term are showing as below:
HKSE:00897'
s Beneish M-Score Range Over the Past 10 Years
Min: -2.98 Med: -2.77 Max: -1.65
Current: -2.81
During the past 13 years, the highest Beneish M-Score of Wai Yuen Tong Medicine Holdings was -1.65. The lowest was -2.98. And the median was -2.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings Beneish M-Score Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings Beneish M-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's Beneish M-Score falls into.
Wai Yuen Tong Medicine Holdings Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Wai Yuen Tong Medicine Holdings for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.9069
+
0.528 * 0.9538
+
0.404 * 1.0384
+
0.892 * 0.917
+
0.115 * 0.9573
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.0123
+
4.679 * -0.040848
-
0.327 * 0.8879
=
-2.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(90.483 / (90.483 + 638.547))
/
(84.147 / (84.147 + 564.894))
=
0.124114
/
0.129648
=
0.9573
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(3.992 - 0
-
70.433)
/
1626.556
=
-0.040848
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Wai Yuen Tong Medicine Holdings has a M-score of -2.81 suggests that the company is unlikely to be a manipulator.
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a Beneish M-Score of -2.81 as of Aug. 23, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #221 out of 914 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Wai Yuen Tong Medicine Holdings' Beneish M-Score too high?
Wai Yuen Tong Medicine Holdings' current Beneish M-Score is -2.81. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #221 out of 914 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #221 out of 914 companies for Beneish M-Score. This places Wai Yuen Tong Medicine Holdings in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. Wai Yuen Tong Medicine Holdings's current Beneish M-Score is -2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.29 — trading right at its estimated fair value. The current Beneish M-Score is -2.81. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current Beneish M-Score is -2.81 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be undervalued.
The current stock price of HK$0.29 is trading 0% below its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Fairly Valued.
Key valuation signals for HKSE:00897:
Beneish M-Score: -2.81
GF Value™: HK$0.29 vs. price of HK$0.29 (0% below fair value)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
38GF Score
Get the complete analysis for HKSE:00897
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
